FDA Must Explain Amgen Exclusivity Denial, Judge Rules
The U.S. Food and Drug Administration may have acted inconsistently when it denied valuable exclusivity for Amgen Inc.'s blockbuster calcium drug Sensipar and must explain its rationale, a D.C. federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article